BriaCell Therapeutics: Funding, Investors & Team (Oct 2026)
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. The company's patented immunotherapy Bria-IMT™ is developed from a breast cancer cell line is an immunotherapy approach that directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. It induces an antitumor response both indirectly and directly by stimulating the immune system which collectively boosts the body’s response. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in a combination with retifanlimab and epacadostat. The company is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for advanced breast cancer. It is founded in New York, New York in 2004.
BriaCell Therapeutics has raised $75.8M across 8 funding rounds on record, the most recent an undisclosed round of $4.7M announced in May 2026.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BriaCell Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2026.
BriaCell Therapeutics Funding Rounds
BriaCell Therapeutics raised $4.0M in an undisclosed round announced in May 2023.
1 years later, an undisclosed round of $5.0M was announced in May 2024.
4 months later, an undisclosed round of $8.5M was announced in Sep 2024.
3 months later, an undisclosed round of $5.5M was announced in Dec 2024.
2 months later, an undisclosed round of $3.1M was announced in Feb 2025.
5 months later, an undisclosed round of $15.0M was announced in Jul 2025.
6 months later, an undisclosed round of $30.0M was announced in Jan 2026.
4 months later, an undisclosed round of $4.7M was announced in May 2026.
BriaCell Therapeutics Founders and Leadership Team
Contact details for the BriaCell Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →BriaCell Therapeutics Funding Compared to Other Biotechnology Startups
BriaCell Therapeutics' latest round of $4.7M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BriaCell Therapeutics in Biotechnology and New York
Companies Similar to BriaCell Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
BriaCell Therapeutics Funding FAQs
What does BriaCell Therapeutics do?
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. The company's patented immunotherapy Bria-IMT™ is developed from a breast cancer cell line is an immunotherapy approach that directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. It induces an antitumor response both indirectly and directly by stimulating the immune system which collectively boosts the body’s response. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in a combination with retifanlimab and epacadostat. The company is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for advanced breast cancer. It is founded in New York, New York in 2004.
How much funding has BriaCell Therapeutics raised?
BriaCell Therapeutics has raised $75.8M across 8 rounds on record. The most recent is an undisclosed round of $4.7M announced in May 2026.
When did BriaCell Therapeutics last raise funding?
BriaCell Therapeutics' most recent funding round on record is an undisclosed round of $4.7M, announced in May 2026.
Who founded BriaCell Therapeutics?
FundedIQ lists Charles Wiseman (Founder) at BriaCell Therapeutics.
Who is the CEO of BriaCell Therapeutics?
William Williams is listed as CEO at BriaCell Therapeutics.
Where is BriaCell Therapeutics headquartered?
BriaCell Therapeutics is based in New York, United States.
How many employees does BriaCell Therapeutics have?
BriaCell Therapeutics is in the 11-50 employee band.
How does BriaCell Therapeutics' funding compare to other Biotechnology startups?
BriaCell Therapeutics' latest round of $4.7M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BriaCell Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BriaCell Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.